logo
Plus   Neg
Share
Email

TLRY Sizzling Hot, IVTY To Be Bought Out, PRQR Up 172% In 6 Days

pharma-071917_11sep18-lt.jpg

The following are some of today's top gainers in the pharma/biotech sector.

1. Invuity Inc. (IVTY)

Invuity is a medical technology company focused on minimal access surgery.

Gained 27.83% to close Tuesday's (Sep.11) trading at $7.35.

News: The Company has entered into an agreement to be acquired by Stryker Corp. (SYK) for $7.40 per share, or a total equity value of approximately $190 million. The transaction is expected to close in the fourth quarter of this year.

2. PLx Pharma Inc. (PLXP)

PLx is a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore 325 mg and Vazalore 81 mg (referred to together as "Vazalore").

Vazalore 325 mg is NDA-approved by the FDA for over the counter distribution and is the first-ever FDA-approved liquid-filled aspirin capsule. The Company is focused on manufacturing, scale-up and label finalization for Vazalore 325 mg aspirin dosage form and preparing an sNDA for Vazalore 81 mg maintenance dose form.

Gained 25.76% to close Tuesday's trading at $4.15.

News: No news

Near-term Catalyst:

The Company will make a presentation at the Janney Healthcare Conference on September 18.

3. Restoration Robotics Inc. (HAIR)

Restoration Robotics is a medical device company developing and commercializing the ARTAS Robotic Hair Restoration System.

Gained 17.50% to close Tuesday's trading at $2.82.

News: No news

Recent event:

On August 16, the Company announced that the underwriters of its previously announced public offering that closed on August 14, 2018, had purchased an additional 1.5 million shares of Restoration Robotics' common stock at a public offering price of $1.50 per share, in connection with the exercise in full of their over-allotment option. The total gross proceeds from the offering were approximately $17.25 million.

4. ProQR Therapeutics N.V. (PRQR)

Gained 15.82% to close Tuesday's trading at $21.60.

News: The Company announced the closing of its previously announced underwritten public offering of 6.61 million ordinary shares at a price to the public of $15.75 per share, including the full exercise of the underwriters' option to purchase additional shares. Gross proceeds from the offering totaled approximately $104.1 million.

Recent event:

-- On September 5, the Company announced positive interim results from its phase I/II trial of QR-110 in patients with Leber's congenital amaurosis 10 (LCA10), the most common cause of blindness due to genetic disease in children. The news sent the stock as much as 120% to $17.55 that day.

Near-term Catalysts:

-- A phase I/II clinical trial of QR-313 in patients that have recessive dystrophic epidermolysis bullosa (RDEB) due to mutations in exon 73 of the COL7A1 gene, dubbed WINGS, is underway. Interim results from this trial are expected in late 2018, with full data expected in 2019.
-- A phase II/III pivotal trial of QR-110 in patients with Leber's congenital amaurosis 10 (LCA10) is expected to start in the first half of 2019.

5. Misonix Inc. (MSON)

Gained 14.51% to close Tuesday's trading at $18.15.

News: No news

Recent event:

On September 6, the Company reported financial results for the fiscal 2018 fourth quarter and year ended June 30, 2018.

Net loss from continuing operations for the year ended June 30, 2018 widened to $7.80 million or $0.87 per share from $1.84 million or $0.22 per share in the prior year. Total revenue for fiscal 2018 jumped to $36.67 million from $27.26 million in fiscal 2017.

Looking ahead, the Company expects double-digit top-line growth to continue in fiscal 2019. The Company anticipates product revenue growth in fiscal 2019 to exceed 20%, with gross profit margins of approximately 70%.

6. Tilray Inc. (TLRY)

Tilray is involved in medical cannabis research, cultivation, processing and distribution, and is focused on becoming a leader in the adult-use cannabis market in Canada once it is legalized. Recreational marijuana is expected to be legalized in Canada on October 17, 2018.

Gained 13.36% to close Tuesday's trading at $95.79.

News: No news

There has been no looking back for Tilray ever since it made its debut on the Nasdaq Global Select Market on July 19, 2018. The stock has gained more than 327% since its IPO.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT